BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

Rhea-AI Summary

BiomX (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the Biomed Israel 2025 conference in Tel Aviv, Israel, from May 20-22, 2025. The presentation will focus on the company's positive topline Phase 2 results for BX211, a phage therapy targeting Staphylococcus aureus in Diabetic Foot Osteomyelitis (DFO). Solomon will deliver an oral presentation titled "Precision Phage Therapy for Chronic Diabetic Foot Infections" during the Immunology & Inflammation session on May 21, 2025, at the InterContinental David Tel Aviv.

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will present at the Biomed Israel 2025 conference, reviewing the Company’s topline Phase 2 results for BX211 in DFO. The conference is being held between May 20 - 22, 2025, in Tel Aviv, Israel.

Presentation Details

Oral Presentation Title	Precision Phage Therapy for Chronic Diabetic Foot Infections
Session	Immunology & Inflammation; Reclaim Top Priorities in BioPharma: Driver and Opportunities?
Session Time/Location:	May 21, 2025, 12:15 – 2:15 pm IST, Hall A, InterContinental David Tel Aviv

“Leading the innovation of phage therapies, BiomX’s programs target persistent, antibiotic-resistant infections in chronic diseases that can result in devastating impacts, including substantially increased morbidity and mortality, for patients,” said Jonathan Solomon, Chief Executive Officer of BiomX. “At Biomed Israel, the premier biopharma conference in the region, we have the opportunity to showcase the positive topline Phase 2 results for our BX211 program in DFO associated with Staphylococcus aureus. We are grateful for key opinion leader endorsements we’ve received and to the organizations that have provided vital support for this program, and we look forward to presenting our BX211 Phase 2 findings at an upcoming, peer-reviewed scientific forum.”

BX211 Topline Phase 2 Trial Results Available: Here

About BX211
BX211 is a phage treatment for the treatment of DFO associated with S. aureus. DFO is a bacterial infection of the bone that usually develops from an infected foot ulcer and is a leading cause of amputation in patients with diabetes. In March 2025, BiomX announced positive topline results from the Phase 2 trial in which BX211 was demonstrated to be safe and well-tolerated and patients receiving BX211 exhibited statistically significant¹ and sustained reduction of ulcer size (PAR)(p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10. In addition, BX211 also produced statistically significant¹ improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline, ulcer depth was classified according to deepest tissue involved as measured by swab) (p=0.048), and in reducing the expansion of ulcer area (p=0.017). Over the 12-week treatment period, all patients (treatment and placebo) were treated in accordance with standard of care, including with systemic antibiotic therapy as appropriate. BiomX is currently planning a Phase 2/3 trial, pending discussions and feedback from the Food and Drug Administration ("FDA").

About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Safe Harbor
This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX refers to its anticipated timing of its future clinical trials as well as the design thereof, expected discussions with the FDA and other regulatory authorities and results thereof, and the potential of its candidates to address the substantial unmet needs of patients with intractable infections, it is using forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. These risks and uncertainties include, but are not limited to, changes in applicable laws or regulations; the possibility that BiomX may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in BiomX’s drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, BiomX’s ability to enroll patients in its clinical trials, and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the FDA and other regulatory authorities; decisions made by investigational review boards at clinical trial sites and publication review bodies with respect to our development candidates; BiomX’s ability to obtain, maintain and enforce intellectual property rights for its platform and development candidates; its potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of BiomX’s cash resources to fund its planned activities for the periods anticipated and BiomX’s ability to manage unplanned cash requirements; and general economic and market conditions. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

Contacts:

BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com

________________________
¹ All p-values described in this release are non-adjusted

FAQ

When will BiomX (PHGE) present their Phase 2 BX211 results at Biomed Israel 2025?

BiomX will present on May 21, 2025, from 12:15 – 2:15 pm IST at Hall A, InterContinental David Tel Aviv.

What is BiomX's BX211 therapy designed to treat?

BX211 is designed to treat Diabetic Foot Osteomyelitis (DFO) associated with Staphylococcus aureus infections.

Who will be presenting BiomX's Phase 2 results at Biomed Israel 2025?

Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting the Phase 2 results.

What type of therapy is BiomX (PHGE) developing?

BiomX is developing natural and engineered phage therapies that target specific pathogenic bacteria.